Clinical trials
for patients

The primary objective of this study is to determine whether lebrikizumab is a safe and effective treatment for people with chronic rhinosinusitis with nasal polyps (CRSNP).

The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy

The aim is to determine whether the drug BI-1206, which has not yet been approved for marketing, will be effective in treating advanced solid tumors and how safe it is for people. In this study, BI-1206 will be administered in combination with pembrolizumab, an approved drug marketed as Keytruda

The purpose of this trial is: to investigate a potential new combination of trial drugs (consisting of the trial drug, which is an antibody-drug conjugate [ADC] called BNT326, in combination with an immunotherapy drug, BNT327) to determine the recommended dose of the trial drug; to evaluate the safety of the combination of study drugs; and to obtain information on its efficacy for advanced or metastatic NSCLC.

The main objectives of this trial are: 1) to evaluate the effect of the study drug on the frequency of seizures in children with Dravet syndrome; 2) to determine whether the study drug affects the impairments caused by Dravet syndrome and how it does so, including behavioral and developmental delays and language and speech difficulties; 3) to assess how long the study drug can reduce the frequency of seizures in children and adolescents with Dravet syndrome (known as “durability”); 4...

The purpose of this study is to determine what dose of the study drug, called CABA-201, can be safely administered to patients with systemic lupus erythematosus (SLE), including those with lupus nephritis (LN).

The purpose of the study is to evaluate the long-term safety and tolerability of iptacopan in participants with primary IgA nephropathy who are receiving open-label iptacopan after completing a Novartis-sponsored pivotal study of iptacopan in IgA nephropathy

The primary objective of this study is to investigate the efficacy and safety of itepekimab in patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

The main objective of the study is to determine the effectiveness of a new prevention strategy for avoiding cytomegalovirus (CMV) infection in patients who have received a kidney transplant.

The purpose of the study is to determine whether iptacopan is safe and has the desired effect in patients with active GPA and PAM (two types of VAA).